mira.patel
TL4 Administrator Co-founder · Documentation · Manchester, UK
Co-founder and documentation lead. My job is turning good threads into maintained pages. If a topic keeps being re-asked, that is a documentation failure and I would like to hear about it. Background in technical writing for analytical instrument vendors.
Joined 16 May 2024 · last posted 10h · groups: staff, moderators, wiki-editors, regional-apac, trust-level-4
193Posts here
7Topics
0Solutions
2.3kLikes received
1kLikes given
33Badges
125Days visited
6.7kPosts read
Recent activity
Full stream-
I joined for one answer and stayed for a year — what changed my mind Replied, post #114 · Start Here › Welcome · 27 Jul 2026 · 9 likes Two things before anyone answers the substance. First, the context in the first post is clear and specific. Second, the question is framed so that an answer can…
-
Revisiting: Liver enzymes drifting down and what that usually means Replied, post #61 · Clinical › Bloodwork · 25 Jul 2026 · 0 likes post #60 is right about the mechanism and I think understates the practical bit. For anyone arriving from a search: the marked solution above is the direct answer, and…
-
Follow-up: Comparing two chromatograms from different laboratories, properly Replied, post #66 · Analytics › HPLC & UHPLC · 24 Jul 2026 · 7 likes Picking up post #63: that is the part I would want checked first. I disagree with the reply above, and I think the disagreement is substantive rather than…
-
Submitting a sample: the process end to end Replied, post #106 · Sourcing › Independent verification · 24 Jul 2026 · 2 likes Picking up post #103: that is the part I would want checked first. Medutest: combined purity and identity reporting. Appears throughout vendor documentation. Where a…
-
Follow-up: Reading an interaction checker output critically Replied, post #58 · Practice › Interactions · 21 Jul 2026 · 2 likes Sulfonylureas and meglitinides: these agents stimulate insulin release and carry hypoglycemia risk. Combining them with semaglutide or tirzepatide requires dose…
-
Restarting after a long gap: what the labelling implies Replied, post #29 · Practice › Dosing & titration · 16 Jul 2026 · 23 likes Reaching a dose and staying there for a year: the question of whether a stable dose remains effective over years is mostly answered by the withdrawal trials and by…
-
Prior authorisation: what the criteria usually require — a second dataset Replied, post #35 · Access › Insurance & coverage · 16 Jul 2026 · 15 likes Worth separating two things that post #31 runs together. Appeals process: unemotional prose, the criterion quoted verbatim, evidence mapped to it point by point, dates,…
-
Prior authorisation: what the criteria usually require — a second dataset Replied, post #30 · Access › Insurance & coverage · 15 Jul 2026 · 0 likes Prior authorisation: pre-approval requirements and how to satisfy them. Most denials cite specific criteria. Understanding the criterion is the first step in satisfying…
-
eGFR fluctuation and the creatinine denominator problem — the long version Replied, post #3 · Clinical › Bloodwork · 15 Jul 2026 · 0 likes TSH and free hormones: TSH is a reasonable screening test but does not tell you about actual free hormone levels. If TSH is abnormal, free thyroid hormones confirm…
-
What consumer-accessible tests can and cannot determine — a second dataset Replied, post #85 · Analytics › Home & field testing · 14 Jul 2026 · 5 likes Coming back to post #83, because the follow-up matters more than the original answer. Enzyme assays: if you have an enzyme that reacts specifically with your compound,…
-
Coming back to: Storing in the door of the fridge is worse than you think Replied, post #6 · Practice › Storage & stability · 11 Jul 2026 · 0 likes I read post #4 twice before replying, because I had assumed the opposite. Two things before anyone answers the substance. First, the context in the first post is clear…
-
Coming back to: Delayed gastric emptying and oral medication absorption: which drugs… Replied, post #12 · Practice › Interactions · 10 Jul 2026 · 13 likes Sulfonylureas and meglitinides: these agents stimulate insulin release and carry hypoglycemia risk. Combining them with semaglutide or tirzepatide requires dose…
Maintains 32 documents
- Semaglutide — referenceReview due 17 Apr 2027
- Retatrutide — referenceReview due 4 Dec 2026
- Liraglutide — referenceReview due 8 Mar 2027
- Orforglipron — referenceReview due 11 Jun 2027
- Oral semaglutide — referenceReview due 24 Jan 2027
- TB-500 — referenceReview due 3 Oct 2026
- Growth-hormone-releasing peptides (GHRP class) — referenceReview due 14 Mar 2027
- Tesamorelin — referenceReview due 21 Aug 2026
- Access notes: FranceReview due 10 May 2027
- Access notes: NetherlandsReview due 9 Aug 2026